Research programme: salt inducible kinase inhibitors - Galapagos NV
Alternative Names: GLPGx; SIK compounds - Galapagos NVLatest Information Update: 11 Aug 2021
At a glance
- Originator Galapagos NV
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Salt-inducible kinase 3 inhibitors; Salt-inducible kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Inflammation
Most Recent Events
- 05 Aug 2021 Galapagos NV plans a clinical trial in 2022
- 22 Jan 2021 Salt inducible kinase inhibitors - Galapagos NV is available for licensing as of 22 Jan 2021. https://www.glpg.com/partnering
- 27 Oct 2020 Early research in Inflammation in Belgium (unspecified route) before October 2020